Identifying Value in the Pharmaceutical Pipeline
The Ripples Group re-prioritized the drug pipeline for an up and coming Life Sciences Company. Soon afterwards and based upon the drug that Ripples had prioritized as #1, the Company won its first big pharma deal worth $1B.
An up and coming Life Sciences Company engaged The Ripples Group to assess its pharmaceutical pipeline from a market perspective. Essentially, they asked, “If we can build it, is it worth anything?”
The Ripples Group carried out detailed research into the Company’s various drug candidates. This effort included interviews with key thought leaders in various therapeutic areas and payers, patient market sizing, an environmental scan of competitor products (existing and in development), price points, and applications, as well as barriers to product approval. Our assessment resulted in a significantly different prioritization of the pipeline than existed at that time. After much debate and discussion, management agreed to The Ripples Group’s recommendations, and the research and development program was adjusted accordingly.
Soon afterwards and based upon the drug candidate that Ripples had prioritized as #1, the Company won its first big deal with a Big Pharma worth $1B. That same year, the Company’s CEO was awarded the Mass High Tech All Star Award.